פרוטין 30

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Compra

Scarica Foglio illustrativo (PIL)
17-08-2016

Principio attivo:

PAROXETINE AS HYDROCHLORIDE

Commercializzato da:

CTS CHEMICAL INDUSTRIES LTD

Codice ATC:

N06AB05

Forma farmaceutica:

טבליה

Composizione:

PAROXETINE AS HYDROCHLORIDE 30 MG

Via di somministrazione:

פומי

Tipo di ricetta:

מרשם נדרש

Prodotto da:

CTS CHEMICAL INDUSTRIES LTD

Gruppo terapeutico:

PAROXETINE

Area terapeutica:

PAROXETINE

Indicazioni terapeutiche:

Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms and prevention of relapse of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia.Treatment of symptoms of social phobia. Post traumatic stress disorder. Generalised anxiety disorders.

Dettagli prodotto:

א. התרופה תינתן לטיפול בכל אחד מאלה: 1. טיפול בהתקפי אימה 2. טיפול בהפרעה אובססיבית כפייתית. 3. טיפול בדיכאון ב. מתן התרופה ייעשה לפי מרשם של רופא מומחה בפסיכיאטריה או בפסיכיאטריה של הילד המתבגר.

Data dell'autorizzazione:

2010-09-30

Foglio illustrativo

                                ±Π∏∂†≠†Â¢Ó˘˙‰†®ÌÈ¯È˘Î˙©†ÌÈÁ˜Â¯‰†˙Â˜˙†ÈÙφÔίˆÏ†ÔÂÏÚ
‡Ù¯†Ì˘¯Ó·†˙·ÈÈÁ†Âʆ‰Ù¯˙
‰Ù¯˙·†ÈØ˘Ó˙˘˙†Ì¯Ë·†ÂÙÂÒ†„Ú†ÔÂÏÚ‰†˙‡†ÔÂÈÚ·†È؇¯˜
≤∞±∞†¯·ÓËÙÒ·†Â„È≠ÏÚ†¯˘Â‡Â†˜„·†ÂÎÂ˙†˙‡ȯ·‰†„¯˘Ó†È¢Ú†Ú·˜†‰Ê†ÔÂÏÚ†ËÓ¯ÂÙ
‚¢Ó†
≤∞†ÔÈ˯Ù
‚¢Ó†
≥∞†ÔÈ˯Ù
˙ÂÈÏ·Ë
˙ÂÈÏ·Ë
∫·Î¯‰
∫‰ÏÈÎÓ†‰ÈϷˆÏÎ
∫‰ÏÈÎÓ†‰ÈϷˆÏÎ
Paroxetine (as HCl) 20 mg
Paroxetine (as HCl) 30 mg
∫ÌÈÏÈÚÙ†È˙Ï·†ÌȯÓÂÁ
Calcium hydrogen phosphate dihydrate, povidone, starch, magnesium
stearate, white opadry, macrogol
∫˙ȇÂÙ¯†˙ÂÏÈÚÙ
Æ˙¯ÊÂÁ†˙ÂÚ¯Ù‰†˙ÚÈÓ†‰„¯Á·†‰ÂÂÏÓ†Ô‡ÎÈ„†ÏÏÂΆ¨ÌÈ‚ÂÒ‰†ÏÎÓ†Ô‡ÎÈ„†Ï˘†ÌÈÓÂËÙÓÈÒ·†ÏÂÙÈËÏ
(Obsessive Compulsive Disorders or OCD)
†˙È˙ÈÈÙΆ˙ÂÓÒ˙†Ï˘†‰¯ÊÁ†˙ÚÈÓ†ÌÈÓÂËÙÓÈÒ·†ÏÂÙÈË
ƉȷÂٯ‚‡†ÈÏ·†Â‡†ÌÚ†‰„¯Á†˙ÂÚ¯Ù‰†Ï˘Â
Post traumatic)
†
‰Ó‡¯Ë†¯Á‡Ï†‰˜ÂˆÓ†È·ˆÓ†¨
(Social phobia)
†˙È˙¯·Á†‰„¯Á†Ï˘†ÌÈÓÂËÙÓÈÒ·†ÏÂÙÈË
.
(Generalised anxiety
disorders)
†‰„¯Á†È·ˆÓ†¨
(stress disorder
.
(SSRI)
†ÔÈÂËÂ¯Ò†Ï˘†˙¯ÊÂÁ†‰ËÈϘ†Ï˘†È·È˘ÏÒ†·ÎÚÓ†∫˙ÈËÈÂÙ¯˙†‰ˆÂ·˜
Ø¯È˘Î˙·†˘Ó˙˘‰Ï†Ôȇ†È˙Ó
˙È‚¯Ï‡†‰·Â‚˙†Íφ‰˙ȉ†Ì‡†Â‡†‰Ù¯˙‰†È·ÈίÓÓ†„Á‡Ï†¯˙Ȇ˙Â˘È‚¯†‰Ú„Ȇ̇†˘Ó˙˘‰Ï†Ôȇ
ƉȷÈίÓÓ†„Á‡Ï
Ê„ÈҘ‡ÈÓ‡ÂÂÓ†ÈÓÏ·†˙ˆ·˜Ó†˙ÂÙ¯˙·†˙ÈÓʆ·†˙Ø
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo inglese 17-08-2016
Scheda tecnica Scheda tecnica inglese 28-08-2017

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti